Cita APA

Li, L. (. X., Cappuzzo, F. (., Matos-García, I. (., Socinski, M. (. A., Hopkins, A. (. M., & Sorich, M. (. J. (2023). Low risk of hyperprogression with first-line chemoimmunotherapy for advanced non-small cell lung cancer: Pooled analysis of 7 clinical trials.

Citación estilo Chicago

Li, L.X. (Lee X.)|||/items/2d3235c9-f3f5-4071-8dd8-253f80848429, F. (Federico)|||/items/29a4a118-e773-45b5-9540-6efe4d49c76e Cappuzzo, I. (Ignacio)|||/items/245b22bb-7d6c-4f39-b623-c35eb8efcf30 Matos-García, M.A. (Mark A.)|||/items/16bac049-5632-4209-82c2-2222b4b58785 Socinski, A.M. (Ashley M.)|||/items/64f5afa8-8b70-4644-b89e-2aa893f05605 Hopkins, y M.J. (Michael J.)|||/items/964ef538-e956-474a-bd19-54a69f04d6a2 Sorich. Low Risk of Hyperprogression With First-line Chemoimmunotherapy for Advanced Non-small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials. 2023.

Cita MLA

Li, L.X. (Lee X.)|||/items/2d3235c9-f3f5-4071-8dd8-253f80848429, et al. Low Risk of Hyperprogression With First-line Chemoimmunotherapy for Advanced Non-small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials. 2023.